Aptamer Group Regulatory News (APTA)

08 December 2022

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

 Investor Webinar

Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces that Dr Arron Tolley, Chief Executive Officer, Dr David Bunka, Chief Technical Officer and Jenny Cutler, Interim Chief Financial Officer, will share an update on the business via the Investor Meet Company platform on 13th Dec 2022 at 2:00pm GMT. No new information will be disclosed during the event.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and meet Aptamer Group via: https://www.investormeetcompany.com/aptamer-group-plc/register-investor

Investors who already follow Aptamer Group on the Investor Meet Company platform will automatically be invited.

- ENDS -

For further information, please contact:

Aptamer Group plc

Dr Arron Tolley +44 (0) 1904 217 404

Consilium Strategic Communications

Matthew Neal / Chris Welsh / Lucy Featherstone +44 (0) 20 3709 5700

aptamergroup@consilium-comms.com

About Aptamer Group plc

Aptamer Group develops custom affinity binders through its proprietary Optimer® platform to enable new approaches in therapeutics, diagnostics and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers through the use of its proprietary Optimer platform.

Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global antibody market is currently worth over $145.0 billion. Optimer binders are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists.

Aptamer Group has successfully delivered projects for global pharma companies, diagnostic development companies, and research institutes covering a range of targets and applications with the objective of establishing royalty-bearing licenses. Through the unique Optimer technology and processes, scientists and collaborators are enabled to make faster, more informed decisions that support discovery and development across the Life Sciences.